Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049087 | 0.81 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL8958368 | 0.81 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL1050458 | 0.81 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL8958437 | 0.81 | CA1 (0.31) | CA1CA2CA9 | |
| SCHEMBL24319938 | 0.78 | — | — | |
| SCHEMBL24319939 | 0.77 | — | — | |
| SCHEMBL16588418 | 0.77 | — | — | |
| SCHEMBL5028794 | 0.75 | — | — | |
| SCHEMBL16588428 | 0.75 | — | — | |
| SCHEMBL996574 | 0.73 | CA1 (0.33) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA LIMITED (GB) | 2016-02-18 | — | — | US | claimed |
| EP-2978318-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | Syngenta Participations AG (CH) | 2016-02-03 | — | — | EP | claimed |
| WO-2014154487-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | WO | claimed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2003010210-A1 | ACTIVATING ORGANOMETALLIC COMPOSITION FOR THE (CO)POLYMERIZATION OF ALPHA-OLEFINS COMPRISING FLUORINATED CYCLOPENTADIENYL COMPOUNDS | POLIMERI EUROPA S.P.A. (IT) | 2003-02-06 | — | — | WO | disclosed |
| US-6274529-B1 | COORDINATION CATALYST CONTAINS METALLOCENE OF HAFNIUM, TITANIUM, OR ZIRCONIUM, AND HETEROCOMPOUND CONTAINING OXYGEN, NITROGEN, SULFUR, AND/OR PHOSPHORUS | ENICHEM S.P.A. (IT) | 2001-08-14 | — | — | US | disclosed |
| US-5744678-A | NICKEL COMPOUND, ORGANOPHOSPHORUS COMPOUND, ORGANOALUMINUM COMPOUND, CARBON-HALOGEN COMPOUNDS; CATALYST SELECTIVITY | NIPPON OIL CO., LTD. (JP) | 1998-04-28 | — | — | US | disclosed |
| US-5728641-A | Catalyst component for the polymerization of olefins | NIPPON OIL COMPANY, LIMITED (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0771822-A1 | Catalytic system for the (co)polymerization of alpha-olefins | ENICHEM S.p.A. (IT) | 1997-05-07 | — | — | EP | disclosed |
| EP-0758563-A1 | OLEFIN OLIGOMERIZATION CATALYST AND PROCESS FOR THE PREPARATION OF OLEFIN OLIGOMER USING IT | NIPPON OIL COMPANY, LTD. (JP) | 1997-02-19 | — | — | EP | disclosed |
| EP-0587440-A2 | Catalyst component for the polymerisation of olefins and process for preparing olefin polymers using same | NIPPON OIL COMPANY, LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-4523009-A | Polyphosphazene compounds and method of preparation | NEILSON ROBERT H | 1985-06-11 | — | — | US | disclosed |
| US-4412053-A | THERMAL DECOMPOSITION OF N-SILYLPHOSPHINIMINES | NEILSON ROBERT H | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CA1 3241/4885CA2 3164/4885CA9 2696/4885 |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | CA1 3324/4885CA2 2946/4885CA9 1352/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | CA1 3241/4885CA2 3164/4885CA9 2696/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | CA1 724/4885CA2 363/4885CA9 970/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | CA1 963/4885CA2 392/4885CA9 720/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | CA1 3324/4885CA2 2946/4885CA9 1352/4885 |
| US-20160046620-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT PESTS | CRY1, DDT, CYC1 | CA1 2549/4885CA2 3074/4885CA9 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.